RxDoctor Payments Data

Tonita Washington

Family · Lawrenceville, GANPI 1306162797

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,059 of the $3,110 with a category attached, or 66.2%. 10 manufacturers reported payments, led by Eli Lilly at 40.1% of the total. Reporting peaked in 2023 at $2,546 and has fallen 91.9% since, to $205 in 2025.

$3,110in general payments, 2019–2025

Across 34 payments — averaging $91.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1K
  • Shionogi Inc$1K
  • Astellas Pharma US Inc$295
  • Lilly USA, LLC$293
  • Hologic Sales And Service, LLC$66
  • Novo Nordisk$32
  • plus $61 from 4 others
$157,691in research payments, 2019–2025

Across 10 payments — averaging $15,769 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$158K

What the payments were for

  • Travel & lodging$2,05966%
  • Food & beverage$96631%
  • Education$853%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,110 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$3,406
Medicare patients
16
Services billed
40

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide83$89,256
EliquisApixaban17$13,451
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$1,612
FenofibrateFenofibrate Nanocrystallized18$747
Albuterol Sulfate HfaAlbuterol Sulfate20$660
Diclofenac Sodium12$514
Amlodipine Besylate87$456
Levothyroxine Sodium42$428
Ibuprofen18$384
Atorvastatin Calcium51$376
Lurasidone Hcl11$365
ClopidogrelClopidogrel Bisulfate19$287
Losartan Potassium27$265
Gabapentin17$257
Nifedipine ErNifedipine15$255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$293$89,25683 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.

Other family in Lawrenceville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →